TickerFacts.

Alector, Inc. (ALEC): Long-Term Debt

Annual figures by period end, from SEC filings.

$10.00M
As of 2025-12-31
2024-12-31: $10.00M2025-12-31: $10.00M$10.00M
2024-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$10.00M0.0%2026-02-25, Balance as of period end
2024-12-31$10.00Mn/a2025-02-26, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Alector, Inc. (ALEC)2025-12-31$10.00M0.0%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$75.00M0.0%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a
TScan Therapeutics, Inc. (TCRX)2025-12-31$32.53M+1.4%
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$54.28Mn/a
Humacyte, Inc. (HUMA)2025-12-31$35.44Mn/a
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$72.44M+0.8%

Compare ALEC, XFOR, EDIT, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗